{"filings":[{"id":1481278,"accession_number":"0001213900-26-075757","cik":2023016,"company_name":"Turn Therapeutics Inc.","ticker":"TTRX","form_type":"8-K","filed_at":"2026-07-07T12:05:25+00:00","items":["7.01","9.01"],"status":"ready","headline":"Turn Therapeutics Announces Final Stage 2 Design and Expansion of GX-03 Phase 2 Trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Interim analysis of GX-03 Phase 2 trial in atopic dermatitis showed Week 4 vIGA-AD Success 71.4% vs 33.3% vehicle in EASI 1.1-7.0 subgroup.","Final Stage 2 design will enroll 120-135 patients across full EASI spectrum (≥1.1) using Hochberg multiple testing procedure for four endpoints.","GX-03 demonstrated favorable safety with no treatment-related serious adverse events or discontinuations reported.","Company expects to complete enrollment in Q4 2026 and is capitalized through Q3 2027.","Turn Therapeutics hosted an investor webcast on July 7, 2026 at 4:30 PM ET to discuss the results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":154897797.58034027,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":814996,"accession_number":"0001213900-26-064405","cik":2023016,"company_name":"Turn Therapeutics Inc.","ticker":"TTRX","form_type":"8-K","filed_at":"2026-06-03T10:12:38+00:00","items":["7.01","9.01"],"status":"ready","headline":"Turn Therapeutics releases investor presentation at Jefferies conference; no new material disclosures","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation dated June 3, 2026, released for the Jefferies Global Healthcare Conference.","Presentation does not contain specific financial or operational updates beyond prior disclosures.","No changes to guidance, pipeline, or corporate strategy reported in the filing or exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":154897797.58034027,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":760077,"accession_number":"0001213900-26-063177","cik":2023016,"company_name":"Turn Therapeutics Inc.","ticker":"TTRX","form_type":"8-K","filed_at":"2026-06-01T12:45:27+00:00","items":["7.01","9.01"],"status":"ready","headline":"Turn Therapeutics GX-03 Phase 2 interim: 92.6% EASI-50 at 4 weeks; no SAEs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["92.6% of GX-03 subjects achieved EASI-50 at 4 weeks vs 65.2% vehicle; 70.4% achieved EASI-75.","EASI-90 rates: 44.4% at Week 4 and 51.9% at Week 8 for GX-03 vs 30.4% and 34.8% vehicle.","No treatment-related serious adverse events, tolerability issues, or discontinuations reported.","Enrollment nearing completion; company optimizing trial endpoints and planning FDA meeting.","Detailed data to be presented at Jefferies Global Healthcare conference on June 4, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":154897797.58034027,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":677836,"accession_number":"0001213900-26-061244","cik":2023016,"company_name":"Turn Therapeutics Inc.","ticker":"TTRX","form_type":"8-K","filed_at":"2026-05-27T12:10:30+00:00","items":["7.01","9.01"],"status":"ready","headline":"Turn Therapeutics announces peer-reviewed publication supporting GX-03's activity in IL-36 inflammatory model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study in murine dermatitis model showed mean IGA score of 1.44 vs 3.00 for untreated controls (p=0.0003) after 7 days of GX-03.","No treatment-related adverse effects observed; IL-36 expression confirmed following Staphylococcus aureus exposure.","Publication in Journal of Dermatological Treatment; first in planned series on GX-03's scientific rationale.","GX-03 is in Phase 2 for moderate-to-severe atopic dermatitis; topline results expected mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":154897797.58034027,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":508997,"accession_number":"0001213900-26-058730","cik":2023016,"company_name":"Turn Therapeutics Inc.","ticker":"TTRX","form_type":"8-K","filed_at":"2026-05-19T12:15:30+00:00","items":["7.01","9.01"],"status":"ready","headline":"Turn Therapeutics CEO to present at Jefferies Global Healthcare Conference June 4","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bradley Burnam, CEO, to present at Jefferies Global Healthcare Conference in New York City on June 4, 2026.","Presentation scheduled from 9:55 AM to 10:25 AM EDT.","Live webcast accessible via Turn Therapeutics investor relations website; replay available for ~6 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":154897797.58034027,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":482637,"accession_number":"0001213900-26-058140","cik":2023016,"company_name":"Turn Therapeutics Inc.","ticker":"TTRX","form_type":"8-K","filed_at":"2026-05-18T12:15:16+00:00","items":["7.01","9.01"],"status":"ready","headline":"Turn Therapeutics appoints former FDA Commissioner Dr. Stephen Hahn as clinical and regulatory lead","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Stephen M. Hahn, former FDA Commissioner, appointed to oversee clinical and regulatory strategy for GX-03.","GX-03 is a topical therapy in Phase 2 trial for moderate-to-severe atopic dermatitis (eczema).","Hahn cited personal family experience with atopic dermatitis as motivation for his role.","CEO Bradley Burnam highlighted Hahn's scientific rigor, regulatory expertise, and patient focus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":154897797.58034027,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":13091,"accession_number":"0001213900-26-054480","cik":2023016,"company_name":"Turn Therapeutics Inc.","ticker":"TTRX","form_type":"8-K","filed_at":"2026-05-11T20:10:24+00:00","items":["2.02","9.01"],"status":"ready","headline":"Turn Therapeutics Q1 net loss $971K; Phase 2 AD trial on track, topline mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $11.2M as of March 31, 2026, up from $5.1M at Dec 31, 2025.","Net loss $970,972 ($0.03 basic EPS) vs $328,547 ($0.01) in Q1 2025.","G&A expenses $1.1M, R&D $109K; total op expenses $1.25M.","Avenue Capital facility provides up to $25M; initial $7M funded March 24, 2026; $18M available on milestones.","Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis; interim analysis Q2 2026, topline mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":154897797.58034027,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111898,"accession_number":"0001213900-26-037470","cik":2023016,"company_name":"Turn Therapeutics Inc.","ticker":"TTRX","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Turn Therapeutics reports FY2025 net loss of $3.2M; secures up to $25M venture debt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $5.08M as of Dec 31, 2025, excludes $7M initial tranche from Avenue Capital facility.","Net loss $3.19M vs $1.77M in 2024; G&A rose to $5.5M from $1.5M on public listing costs.","Phase 2 trial of GX-03 for atopic dermatitis on track; topline results expected mid-2026.","Appointed former CDC Director Dr. Robert Redfield and Martin Dewhurst (ex-McKinsey) to leadership/board.","Entered global license, supply, and distribution agreement with Medline; revenue expected to begin late 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":154897797.58034027,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111897,"accession_number":"0001213900-26-033233","cik":2023016,"company_name":"Turn Therapeutics Inc.","ticker":"TTRX","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Turn Therapeutics secures up to $25M growth capital loan from Avenue Capital Group","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $7M tranche funded at closing; up to $18M additional available upon clinical and corporate milestones.","Interest rate = greater of prime + 5.50% or 12.25%; maturity October 1, 2029; no financial covenants.","Lender receives $1.2M equity grant and conversion option up to $3M principal at 80% of closing price.","Proceeds expected to extend runway through Phase 2 atopic dermatitis readout and support GX-03 registrational trials.","Company anticipates full financing extends runway through end of 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":154897797.58034027,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111896,"accession_number":"0001213900-26-016916","cik":2023016,"company_name":"Turn Therapeutics Inc.","ticker":"TTRX","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Turn Therapeutics appoints former CDC Director Dr. Robert Redfield as Senior Advisor for GX-03","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Redfield appointed Senior Advisor of Health Policy and Regulatory Affairs, effective immediately.","He will provide strategic guidance on clinical development and regulatory positioning of lead candidate GX-03.","GX-03 is currently in Phase 2 clinical trials for dermatologic inflammatory conditions.","Dr. Redfield served as 18th Director of the CDC (2018-2021) and led federal public health responses.","Turn Therapeutics is a clinical-stage biotech focused on targeted inflammatory and immunology therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":154897797.58034027,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111895,"accession_number":"0001213900-26-013490","cik":2023016,"company_name":"Turn Therapeutics Inc.","ticker":"TTRX","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Turn Therapeutics announces presentations at TD Cowen and Oppenheimer healthcare conferences","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Brad Burnam to present at 46th Annual TD Cowen Healthcare Conference in Boston on March 2, 2026.","Also presenting virtually at 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026.","Company to provide update on Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis.","Updated investor presentation posted on company website on February 9, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":154897797.58034027,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111894,"accession_number":"0001213900-26-003153","cik":2023016,"company_name":"Turn Therapeutics Inc.","ticker":"TTRX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Turn Therapeutics provides pipeline update; GX-03 Phase 2 data expected H1 2026, appoints Martin Dewhurst to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 trial of GX-03 for moderate-severe atopic dermatitis on track; interim and topline data expected first half of 2026.","Martin Dewhurst (30+ year McKinsey M&A veteran) appointed to Board of Directors.","Vaccine pipeline expanded to include intranasal influenza candidate; in-vivo/vitro studies start Q1 2026.","Commercial partnership with Medline expected to generate near-term revenue in 2026 in wound care.","Strengthened balance sheet via share purchase agreement extends cash runway into late 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":154897797.58034027,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111893,"accession_number":"0001213900-26-002173","cik":2023016,"company_name":"Turn Therapeutics Inc.","ticker":"TTRX","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Turn Therapeutics appoints Martin Dewhurst to its Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 5 to 6 members; Dewhurst appointed as independent Class III director effective Jan 7, 2026.","Over 30 years life sciences experience; former McKinsey senior partner and co-leader of global life sciences practice.","Received initial RSU grant with $100,000 fair value, vesting at one year or change of control.","Will chair compensation committee; eligible for annual $70,000 RSU grant after first anniversary of direct listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":154897797.58034027,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128523,"accession_number":"0001213900-25-109580","cik":2023016,"company_name":"Turn Therapeutics Inc.","ticker":"TTRX","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Turn Therapeutics Q3 net loss $1.9M; enters global Medline PermaFusion deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.9M ($0.07/share) vs $0.67M loss in Q3 2024; G&A surged to $1.75M on listing costs.","Cash and equivalents $3.11M at Sept 30, 2025, up from $0.87M at Dec 31, 2024.","Closed global supply/development/license agreement with Medline for PermaFusion platform.","Started trading on Nasdaq under TTRX on Oct 8, 2025; appointed two new board members.","Commenced clinical trial of topical IL-36/IL-31 inhibitor for eczema."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":154897797.58034027,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128522,"accession_number":"0001213900-25-108655","cik":2023016,"company_name":"Turn Therapeutics Inc.","ticker":"TTRX","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"GX-03 named one of five novel mechanisms in atopic dermatitis by Patient Care Online","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GX-03 technology recognized by Patient Care Online alongside candidates from Amgen, Sanofi, Leo Pharma, Apogee, and Nektar.","CEO states GX-03 is first topical IL-36/IL-31 inhibitor; topline data for severe eczema expected early 2026.","CEO Bradley Burnam interviewed former CDC Director Dr. Robert Redfield on podcast about restoring trust in science."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":154897797.58034027,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128521,"accession_number":"0001213900-25-106265","cik":2023016,"company_name":"Turn Therapeutics Inc.","ticker":"TTRX","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Turn Therapeutics Appoints Andrew Scott as VP of Corporate Communications","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Scott appointed VP of Corporate Communications effective November 4, 2025.","Scott will oversee IR, capital markets strategy, and licensing partnerships.","He joins from ThinkEquity LLC, where he was Managing Director of Investment Banking.","Scott has helped raise approximately $3 billion across life-sciences transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":154897797.58034027,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128520,"accession_number":"0001104659-25-104028","cik":2023016,"company_name":"Turn Therapeutics Inc.","ticker":"TTRX","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Turn Therapeutics enters global supply, development, and license agreement with Medline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement covers development, manufacture, and commercialization of products using Turn's PermaFusion delivery platform.","Medline is the largest provider of medical-surgical products and supply chain solutions in the U.S.","Financial terms, product categories, and development timelines remain confidential per agreement terms.","CEO Bradley Burnam calls partnership a 'transformative milestone' to accelerate entry into professional and consumer markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":154897797.58034027,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128519,"accession_number":"0001104659-25-103160","cik":2023016,"company_name":"Turn Therapeutics Inc.","ticker":"TTRX","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Turn Therapeutics enters global supply and development pact with Medline for PermaFusion platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Turn grants Medline exclusive worldwide license to use Turn's 510(k) clearance for wound-care field-of-use.","Medline to lead global commercialization across 100+ countries; Turn provides formulation expertise, IP, and clinical development.","Initial term of three years with automatic one-year renewals; exclusivity subject to undisclosed volume thresholds.","Parties to collaborate on line extensions (foams, films, hydrogels, ointments, dressings) incorporating PermaFusion technology.","Public announcement required within 72 hours of October 23, 2025 effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":154897797.58034027,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128518,"accession_number":"0001104659-25-101410","cik":2023016,"company_name":"Turn Therapeutics Inc.","ticker":"TTRX","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Turn Therapeutics updates on GX-03 phase 2 eczema trial: 25% enrolled, topline 2026; $85M GEM facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 trial of GX-03 (topical IL-36/IL-31 inhibitor) for moderate-severe eczema: ~25% of targeted sample completed, no safety concerns; topline results expected in 2026.","Company completed dilution-sparing direct listing with $85M GEM Global Yield on-demand financing vehicle to reduce reliance on future equity offerings.","Intranasal vaccine initiative advancing; in-vivo studies scheduled to commence in Q4 2025.","Shareholder webinar held today, October 22, 2025 at 2:00 PM ET to review milestones and capital strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":154897797.58034027,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128517,"accession_number":"0001104659-25-096003","cik":2023016,"company_name":"Turn Therapeutics Inc.","ticker":"TTRX","form_type":"8-K","filed_at":"2025-10-02T23:59:59+00:00","items":["1.01","3.03","5.03","5.02","9.01"],"status":"ready","headline":"Turn Therapeutics effects direct listing on Nasdaq; appoints two independent directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SEC declared effective S-1 for direct listing of up to 17,868,760 shares of common stock on Nasdaq Global Market.","Entered Stockholders Agreement with CEO Bradley Burnam and BEB Holdings requiring holder consent for major actions while they hold >=10% shares.","Granted registration rights to CEO/BEB Holdings including demand and piggyback registration rights.","Appointed Arthur Golden and Dr. Kent Kester as independent directors; Golden chairs Compensation Committee, Kester on Audit and Compensation.","Executed employment agreements with CEO Bradley Burnam and Zuraiz Chaudhary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":154897797.58034027,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}